HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: a two-site study
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Contrary to the minimal criteria proposed by the International Society for Cell and Gene Therapy for defining multipotent mesenchymal stromal cells (MSC), human leukocyte antigen (HLA)-DR expression is largely unpredictable in ex vivo-expanded clinical-grade cultures. Although activation of MSC in culture does not appear to affect their functionality, a large study investigating the impact of HLA-DR expression on cell identity and potency is still missing in the literature. METHODS: A retrospective analysis of HLA-DR expression in 130 clinical batches of bone marrow (BM)-MSC from two independent Good Manufacturing Practice-compliant production facilities was performed in order to identify the consequences on critical quality attributes as well as potential activation cues and dynamics of MSC activation in culture. RESULTS: cells in culture were confirmed to maintain fibroblastic morphology, mesenchymal phenotype identity, multipotency in vitro, and immunomodulatory capacity. Interestingly, the use of either human sera or platelet lysate supplements resulted in similar results. CONCLUSIONS: HLA-DR expression should be considered informative rather than as a criterion to define MSC. Further work is still required to understand the impact of HLA-DR expression in the context of product specifications on BM-MSC qualities for clinical use in specific indications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similar findings have been previously reported by Grau-Vorster et al. who revealed variability in BM-MSC preparations for clinical applications, concluding that the absence or presence of HLA-DR does not have an impact on the overall properties of the cells [34].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Galipeau, J., & Sensébé, L. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.05.004 · Cited by 1,819
Le Blanc, K., Tammik, C., Rosendahl, K., Zetterberg, E., & Ringdén, O. (2003) · Experimental Hematology · doi:10.1016/s0301-472x(03)00110-3 · Cited by 1,623
Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine
Murphy, M. B., Moncivais, K., & Caplan, A. I. (2013) · Experimental & Molecular Medicine · doi:10.1038/emm.2013.94 · Cited by 1,231
Mesenchymal stem cells avoid allogeneic rejection
Ryan, J. M., Barry, F. P., Murphy, J. M., & Mahon, B. P. (2005) · Journal of Inflammation · doi:10.1186/1476-9255-2-8 · Cited by 714
Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation
Galleu, A., Riffo-Vasquez, Y., Trento, C., Lomas, C., Dolcetti, L., Cheung, T. S., von Bonin, M., Barbieri, L., Halai, K., Ward, S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7828 · Cited by 646
IFN‐γ activation of mesenchymal stem cells for treatment and prevention of graft versus host disease
Polchert, D., Sobinsky, J., Douglas, G., Kidd, M., Moadsiri, A., Reina, E., Genrich, K., Mehrotra, S., Setty, S., Smith, B., et al. (2008) · European Journal of Immunology · doi:10.1002/eji.200738129 · Cited by 581
MSC-Based Product Characterization for Clinical Trials: An FDA Perspective
Mendicino, M., Bailey, A. M., Wonnacott, K., Puri, R. K., & Bauer, S. R. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.01.013 · Cited by 497
Activation, homing, and role of the mesenchymal stem cells in the inflammatory environment
Zachar, L., Bačenková, D., & Rosocha, J. (2016) · Journal of Inflammation Research · doi:10.2147/jir.s121994 · Cited by 191
Cell, tissue and gene products with marketing authorization in 2018 worldwide
Cuende, N., Rasko, J. E. J., Koh, M., Dominici, M., & Ikonomou, L. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.09.010 · Cited by 118
Cited by
Fričová, D., Korchak, J. A., & Zubair, A. C. (2020) · npj Regenerative Medicine · doi:10.1038/s41536-020-00106-y · Cited by 80
Guadix, J. A., López‐Beas, J., Clares, B., Soriano-Ruiz, J. L., Zugaza, J. L., & Gálvez‐Martín, P. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11110552 · Cited by 73
Gromolak, S., Krawczenko, A., Antończyk, A., Buczak, K., Kiełbowicz, Z., & Klimczak, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249726 · Cited by 63
“They reported that the multilineage differentiation and immunomodulatory potential of MSCs was independent of their HLA DR expression level [41].”
BackgroundCalcat-i-Cervera, S., Rendra, E., Scaccia, E., Amadeo, F., Hanson, V., Wilm, B., Murray, P., O’Brien, T., Taylor, A., & Bieback, K. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03352-1 · Cited by 56
“who revealed variability in BM-MSC preparations for clinical applications, concluding that the absence or presence of HLA-DR does not have an impact on the overall properties of the cells [34].”
BackgroundImmunogenicity of mesenchymal stromal/stem cells
Chen, W., Lv, L., Chen, N., & Cui, E. (2023) · Scandinavian Journal of Immunology · doi:10.1111/sji.13267 · Cited by 58
Metadata
- Authors
- Grau-Vorster, M., Laitinen, A., Nystedt, J., & Vives, J.
- Affiliations
- Universitat Autònoma de Barcelona (ES)
- Finnish Red Cross (FI)
- Corresponding author
- Nystedt, Johanna
- Vives, Joaquim
- Venue
- Stem Cell Research & Therapy
- Published
- 2019-06-13
- Volume
- 10
- Issue
- 1
- Pages
- 164-164
- ISSN
- 1757-6512 (ISSN-L)
- PMC
- PMC6567533
- OpenAlex
- W2952930570
- Cited by
- 61
- References
- 24
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 11 · 2023: 13 · 2022: 7 · 2021: 11 · 2020: 9 · 2019: 2
- FWCI
- 3.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Stem Cell Research & Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Dentistry › Periodontics › Periodontal Regeneration and Treatments
- Keywords
- HLA-DR expression, multipotent mesenchymal stromal cells, bone marrow-derived stromal cells, critical quality attributes, platelet lysate, ex vivo cell expansion
- MeSH terms
- Bone Marrow Cells, Cell Differentiation, Cell Survival, Cells, Cultured, HLA-DR Antigens, Humans, Interferon-gamma, Retrospective Studies, Apoptosis, Mesenchymal Stem Cells, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: a two-site study. https://app.cochat.ai/papers/10.1186/s13287-019-1279-9
- The paper
- Grau-Vorster, M., Laitinen, A., Nystedt, J., & Vives, J. (2019). HLA-DR expression in clinical-grade bone marrow-derived multipotent mesenchymal stromal cells: a two-site study. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-019-1279-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.